DACRIN logo

Open to recruitment

Looking to participate in a DACRIN study? Below are links to eligibility information, participating organisations, and contact details for all currently open trials. Additionally, we offer an online search tool called ClinTrial Ref, which can help clinicians and patients you easily find the right study.

Study title Lead group Study details
DACRIN 2021-4: The National Australian HCV Point-of-Care Testing Program (HCVPOCT). DACRIN contributing participants. The Kirby InstituteClinicalTrials.gov NCT05042544
DACRIN 2021-3: Enhancing hepatitis C testing and treatment among people who inject drugs attending needle and syringe programs (TEMPO). DACRIN contributing participants The Kirby InstituteClinicalTrials.gov NCT04014179
DACRIN 2021-1: Impact of long-acting depot buprenorphine on the high-risk post release period for people with opioid dependence (The Release Study)DACRIN (HNELHD) Contact us

Closed to recruitment

Our ongoing data collection continues even though we are no longer accepting new participants for these DACRIN studies.

Study titleLead groupStudy details
DACRIN 2020-4: A trial of the effectiveness of vaporised nicotine products for smoking cessation amongst NSW opiate agonist treatment clients (HARMONY)DACRIN (HNELHD)Australia New Zealand Clinical Trials Registry ACTRN12621000148875
DACRIN 2019-3: Examining clinical outcomes and quality indicators for clients attending NSW public alcohol and other drug (AOD) treatment services (COQI Cohort Study)DACRIN (SESLHD) COQI Program
DACRIN 2017-5: ETHOS Engage: Enhancing treatment of Hepatitis C in Opioid Substitution Setting II (ETHOS II) partnership project to enhance hepatitis C care in drug and alcohol clinics The Kirby Institute Conway, Valerio et al. 2021
Valerio, Alavi et al. 2021
Conway, Valerio et al. 2022
Valerio, Alavi et al. 2022

Analyses underway

The data collection phase of the DACRIN studies below has been successfully completed. Our researchers or partners are currently working on analysing the data and preparing manuscripts for publication.

Study title Lead group Study details
DACRIN 2022-4: Investigating staff attitudes, knowledge, and perspectives regarding cannabis use by clients in NSW Opioid Treatment Programs: A Staff SurveyDACRIN (SESLHD) Contact us
DACRIN 2022-3: Case Mix Variables Project
 University of Wollongong
 Contact us
DACRIN 2021-2: Microdosing with buprenorphine to transfer from methadone to buprenorphine in adults with opioid dependence - a prospective non-randomised open label clinical trial DACRIN (SLHD)Australia New Zealand Clinical Trials Registry ACTRN12622000444785
​DACRIN 2020-5: Characterizing withdrawal from depot buprenorphine: an observational case series of withdrawal from Buvidal​DACRIN (SESLHD)​Australia New Zealand Clinical Trials Registry ACTRN12621001011875
DACRIN 2019-6: Alcohol and Other Drugs (AOD) client concerns and wishes regarding cognitive impairment treatment (AOD Cog) DACRIN (NLHD) Contact us
DACRIN 2019-4: Driving perspectives, behaviours and concerns of consumers receiving opioid treatmentDACRIN (SLHD) Contact us
DACRIN 2019-2: Developing a clinical data laboratory for methamphetamine use in NSW: the MAData project. DACRIN (SESLHD) Black, Mammen et al. 2022
Black, Bruno et al. 2023
DACRIN 2017-4: Incentives to quit tobacco in pregnancy (iQuip)DACRIN (HNELHD)Australia New Zealand Clinical Trials Registry ACTRN12618000576224
DACRIN 2016-5: Improving alcohol treatment outcomes: The impact of client, intervention and system variables on treatment outcomes (Alcohol Treatment Centre study) University of Newcastle Contact us
DACRIN 2016-4: Defining the clinical role of topirimate in the treatment of alcohol dependence in Australia DACRIN (SLHD) Morley, Kranzler et al. 2018
DACRIN 2016-3: A randomised double-blind placebo-controlled study of lisdexamphetamine for the treatment of methamphetamine dependence (The LiMA study)DACRIN (SVHN) Ezard, Dunlop at al. 2018

Find out more on upcoming DACRIN studies.

Learn about past DACRIN studies.


Current as at: Tuesday 19 December 2023
Contact page owner: Centre for Alcohol and Other Drugs